Investigational drug · Phase 2
MHB034C
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignant Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "MHB034C"
First trial start
2026
Dec 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MHB034C", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignant Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MHB034C" as an intervention, largest first.
- A Clinical Study of MHB034C for Injection in Participants With Advanced Solid TumorsNot yet recruiting
Minghui Pharmaceutical (Shanghai) LTDIndustry
NCT07928570 · 400 participants (planned) · Start Dec 20, 2026 · Primary completion Jun 15, 2028
Drug: MHB034C for Injection · For: Advanced Malignant Solid Tumor
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Malignant Solid Tumor
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- SCTB41Phase 36 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor
- PRL3-ZUMABPhase 34 trials
Intra-IMMUSG Pte Ltd · Advanced Malignant Solid Tumor, Solid Tumor, Advanced Solid Cancers
- MHB039APhase 24 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer
- MHB036CPhase 23 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Breast Cancer, Advanced Malignant Solid Tumor, Advanced Lung Cancer
- Recombinant Human IL1215-PDL1B Oncolytic HSV-1, VG161Phase 23 trials
CNBG-Virogin Biotech (Shanghai) Ltd. · Advanced Malignant Solid Tumor, Sarcoma, Advanced Intrahepatic Cholangiocarcinoma
- PD-L1 monoclonal antibodyPhase 22 trials
Suzhou BlueHorse Therapeutics Co., Ltd. · Non-Small Cell Lung Cancer, Advanced Malignant Solid Tumor
- SCTB39-1Phase 22 trials
Sinocelltech Ltd. · Advanced Malignant Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.